Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Nasal congestion, Oropharyngeal pain, Rhinorrhoea
Clinical narrative: Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose; Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose; Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose; Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose; This spontaneous case was reported by a nurse and describes the occurrence of COVID-19 (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose), OROPHARYNGEAL PAIN (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose), NASAL CONGESTION (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose) and RHINORRHOEA (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002H21A) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Patient not had any drug allergy.  The patient's past medical history included Myocardial infarction (MI 2017) in 2017. Concomitant products included BUPROPION, ESTROGEN NOS;METHYLTESTOSTERONE, CLOPIDOGREL, LOSARTAN, METOPROLOL, ATORVASTATIN and FAMOTIDINE for an unknown indication.   On 04-Apr-2022 at 4:00 PM, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On 27-May-2022 at 8:00 AM, the patient experienced OROPHARYNGEAL PAIN (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose), NASAL CONGESTION (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose) and RHINORRHOEA (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose). On an unknown date, the patient experienced COVID-19 (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose). At the time of the report, COVID-19 (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose) outcome was unknown and OROPHARYNGEAL PAIN (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose), NASAL CONGESTION (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose) and RHINORRHOEA (Although patient was symptom free following Paxlovid treatment, developed sore throat, nasal congestion and runny nose) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment drugs were reported COMPANY COMMENT: This is an spontaneous case concerning a 74-years-old female patient with medical history of Myocardial infarction in 2017, Concomitant products included BUPROPION, ESTROGEN NOS; METHYLTESTOSTERONE, CLOPIDOGREL, LOSARTAN, METOPROLOL, ATORVASTATIN and FAMOTIDINE, PAXLOVID) for COVID-19 treatment from 17 to 22 May, 2022 who experienced the unexpected events of COVID-19  (AESI), OROPHARYNGEAL PAIN, RHINORRHOEA  and NASAL CONGESTION 53 days after 4th  dose of  mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: COMPANY COMMENT: This is an spontaneous case concerning a 74-years-old female patient with medical history of Myocardial infarction in 2017, Concomitant products included BUPROPION, ESTROGEN NOS; METHYLTESTOSTERONE, CLOPIDOGREL, LOSARTAN, METOPROLOL, ATORVASTATIN and FAMOTIDINE, PAXLOVID) for COVID-19 treatment from 17 to 22 May, 2022 who experienced the unexpected events of COVID-19  (AESI), OROPHARYNGEAL PAIN, RHINORRHOEA  and NASAL CONGESTION 53 days after 4th  dose of  mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.